Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ809811-0,55
KB0,00
PKN64,0664,160,34
Msft-0,04
Nokia4,674,7495-0,30
IBM-0,26
Mercedes-Benz Group AG62,3662,38-0,21
PFE0,74
25.11.2022 23:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 25.11.2022 20:19:58
Eisai Depository Receipt (US Other OTC (Pink Sheets))
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
68,10 2,50 1,66 22 751
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 26.11.2022
Popis společnosti
Obecné informace
Název společnostiEisai Co Ltd (ADR)
TickerESALY
Kmenové akcie:ADR
RICESALY.PK
ISIN-
Poslední známé roční výsledky31.03.2022
Poslední známé čtvrtletní výsledky30.09.2022
Počet zaměstnanců k 31.03.2022 11 322
Akcie v oběhu k 30.09.2022 286 900 846
MěnaJPY
Kontaktní informace
UliceEisai Main Bldg., 4-6-10, Koishikawa
MěstoBUNKYO-KU
PSČ112-8088
ZeměJapan
Kontatní osoba 
Funkce kontaktní osoby 
Telefon81 338 173 700
Fax81338113305

Business Summary: Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
Financial Summary: BRIEF: For the six months ended 30 September 2022, Eisai Co Ltd (ADR) revenues decreased 1% to Y358.63B. Net income applicable to common stockholders decreased 34% to Y30.47B. Revenues reflect Other Business segment decrease of 90% to Y6.06B. Net income also reflects Other Business segment income decrease of 98% to Y1.27B, Eliminations and Corporate segment loss increase of 27% to Y169.03B. Dividend per share increased from Y161.46 to Y165.23.
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSProcess, Physical Distribution, and Logistics Consulting Services
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Process, Phys Dist & Log Consulting Services
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Process, Physical, Distribution and Logistics Consulting Services
SICPharmaceutical Preparations
SICManagement Consulting Services



  • Poslední aktualizace: 26.11.2022
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board of Directors, Independent DirectorYasuhiko Kato74
Chief Executive Officer, Representative Executive Officer, DirectorHaruo Naito74
Managing Executive Officer, Chief Financial Officer, Chief IR OfficerTatsuyuki Yasuno54
Representative Executive Officer, Chief Operating OfficerYasushi Okada63
Executive Officer, Chief Human Resource OfficerTeruyuki Masaka44
Senior Managing Executive Officer, General Counsel, President of SubsidiaryKenta Takahashi62
Managing Executive Officer, Chief Government Relations OfficerMasatomi Akana55
Managing Executive Officer, President of Neurology Business Group, Global AD Officer, President of Americas Region, Chairman & CIvan Cheung45
Managing Executive OfficerYanhui Feng49
Managing Executive Officer, President of EMEA Region, Chairman & Chief Executive Officer of SubsidiaryGary Hendler55